docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2023-22-4-18-23docru-175Research ArticleКАРДИОМЕТАБОЛИЧЕСКАЯ МЕДИЦИНАCARDIOMETABOLIC MEDICINEАдипоцитокины сквозь призму метаболических фенотипов человекаAdipocytokines Through the Prism of Human Metabolic Phenotypeshttps://orcid.org/0000-0002-1645-5523АлфёроваВ. И.AlferovaV. I.

Алфёрова Влада Игоревна — аспирант, врач-эндокринолог НИИТПМ — филиал ФГБНУ «ФИЦ ИЦиГ СО РАН»

630089,  г. Новосибирск, ул. Бориса Богаткова, д. 175/1

175/1 Boris Bogatkov Str., Novosibirsk, 630089

lady.alfyorova2009@yandex.ruhttps://orcid.org/0000-0003-4716-876XМустафинаС. В.MustafinaS. V.

Мустафина Светлана Владимировна — д. м. н., ведущий научный сотрудник лаборатории клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний НИИТПМ — филиал ФГБНУ «ФИЦ ИЦиГ СО РАН»

630089, г. Новосибирск, ул. Бориса Богаткова, д. 175/1

175/1 Boris Bogatkov Str., Novosibirsk, 630089

svetlana3548@gmail.comНаучно-исследовательский институт терапии и профилактической медицины — филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук»РоссияResearch Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of SciencesRussian Federation202317022025224КАРДИОМЕТАБОЛИЧЕСКАЯ МЕДИЦИНА1823Copyright © Алфёрова В.И., Мустафина С.В., 20252025Алфёрова В.И., Мустафина С.В.Alferova V.I., Mustafina S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/175Цель обзора

Цель обзора: изучить, по данным литературы, особенности уровней адипонектина, лептина, резистина, адипсина, интерлейкина 6 и фактора некроза опухоли α у лиц с метаболически здоровым и нездоровым фенотипом при разных значениях массы тела.

Основные положения

Основные положения. Представлены результаты зарубежных и отечественных исследований уровней адипоцитокинов при метаболически здоровом и нездоровом фенотипах у лиц с различной массой тела. Рассмотрены такие адипоцитокины, как адипонектин, лептин, резистин, адипсин, интерлейкин 6, фактор некроза опухоли α. Приводятся данные о патогенетических и клинических особен ностях выработки этих биологически активных веществ и их влияния на метаболизм. Проанализированы тематические источники из баз данных PubMed, РИНЦ.

Заключение

Заключение. По литературным данным, с метаболически нездоровым фенотипом ассоциированы высокие уровни лептина, резистина, фактора некроза опухоли α, интерлейкина 6, с метаболически здоровым — адипонектина, адипсина. 

Aim

Aim: To study the features of adiponectin, leptin, resistin, adipsin, interleukin 6, and tumor necrosis factor α levels in individuals with a metabolically healthy and unhealthy phenotype at different values of body weight according to the literature.

Key points

Key points. The results of foreign and domestic studies of the levels of adipocytokines in metabolically healthy and unhealthy phenotypes in individuals with different body weights are presented. Adipokines such as adiponectin, leptin, resistin, adipsin, interleukin 6, and tumor necrosis factor α were analyzed. Data are given on the pathogenetic and clinical features of the production of these biologically active substances and their effect on metabolism.

Conclusion

Conclusion. According to the literature, high levels of leptin, resistin, tumor necrosis factor α, interleukin 6 are associated with a metabolically unhealthy phenotype, and adiponectin, adipsin are associated with a metabolically healthy phenotype. 

адипокиныметаболически здоровое ожирениеметаболически нездоровое ожирениеадипонектинлептинрезистинадипсининтерлейкин 6фактор некроза опухоли α.adipokinesmetabolically healthy obesitymetabolically unhealthy obesityadiponectinleptinresistinadipsininterleukin 6tumor necrosis factor α.ReferencesАлфёрова В.И., Мустафина С.В. Распространенность ожирения во взрослой популяции Российской Федерации (обзор литературы). Ожирение и метаболизм. 2022;19(1):96–105. DOI: 10.14341/omet12809Alferova V.I., Mustafina S.V. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and Metabolism. 2022;19(1):96–105. (in Russian). DOI: 10.14341/omet12809Симонова Г.И., Мустафина С.В., Рымар О.Д., Щербакова Л.В. и др. Метаболический синдром, риск общей и сердечно-сосудистой смертности по данным четырнадцатилетнего проспективного когортного исследования в Сибири. Российский кардиологический журнал. 2020;25(6):3821. DOI: 10.15829/1560-4071-2020-3821Simonova G.I., Mustafina S.V., Rymar O.D., Scherbacova L.V. et al. Metabolic syndrome and the risk of cardiovascular and all-cause mortality: data of 14-year prospective cohort study in Siberia. Russian Journal of Cardiology. 2020;25(6):3821. (in Russian). DOI: 10.15829/1560-4071-2020-3821Muñoz-Garach A., Cornejo-Pareja I., Tinahones F.J. Does metabolically healthy obesity exist? Nutrients. 2016;8(6):320. DOI: 10.3390/ nu8060320Muñoz-Garach A., Cornejo-Pareja I., Tinahones F.J. Does metabolically healthy obesity exist? Nutrients. 2016;8(6):320. DOI: 10.3390/ nu8060320Мустафина С.В., Винтер Д.А., Рымар О.Д., Щербакова Л.В. и др. Фенотипы ожирения и риск развития инфаркта миокарда, по данным проспективного когортного исследования. Российский кардиологический журнал. 2019;6:109–14. DOI: 10.15829/1560-4071-2019-6-109-114Mustafina S.V., Vinter D.A., Rymar O.D., Scherbacova L.V. et al. Obesity phenotypes and the risk of myocardial infarction: a prospective cohort study. Russian Journal of Cardiology. 2019;6:109–14. (in Russian). DOI: 10.15829/1560-4071-2019-6-109-114Романцова Т.И., Островская Е.В. Метаболически здоровое ожирение: дефиниции, протективные факторы, клиническая значимость. Альманах клинической медицины. 2015;1(1):75–86. DOI: 10.18786/2072-0505-2015-1-75-86Romantsova T.I., Ostrovskaya E.V. Metabolically healthy obesity: definitions, protective factors, clinical relevance. Almanac of Clinical Medicine. 2015;1(1):75–86. (in Russian). DOI: 10.18786/2072-0505-2015-1-75-86Phillips C.M. Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. Ann. N. Y. Acad. Sci. 2017;1391(1):85–100. DOI: 10.1111/nyas.13230Phillips C.M. Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. Ann. N. Y. Acad. Sci. 2017;1391(1):85–100. DOI: 10.1111/nyas.13230Спиридонов А.Н., Худякова А.Д., Рагино Ю.И. Адипокины/цитокины и нарушения липидного обмена. Атеросклероз. 2022;18(2):157–64. DOI: 10.52727/2078-256X-2022-18-2-157-164Spiridonov A.N., Khudiakova A.D., Ragino Yu.I. Adipokines/cytokines and disturbances in lipid metabolism. Ateroscleroz. 2022;18(2):157– 64. (in Russian). DOI: 10.52727/2078-256X-2022-18-2-157-164Рябова Е.А., Рагино Ю.И. Провоспалительные адипокины и цитокины при абдоминальном ожирении как фактор развития атеросклероза и патологии почек. Атеросклероз. 2021;17(4):101–10. DOI: 10.52727/2078-256X-2021-17-4-101-110Ryabova E.A., Ragino Yu.I. Proinflammatory adipokines and cytokines in abdominal obesity as a factor in the development of atherosclerosis and renal pathology. Ateroscleroz. 2021;17(4):101–10. (in Russian). DOI: 10.52727/2078-256X-2021-17-4-101-110Khoramipour K., Chamari K., Hekmatikar A.A., Ziyaiyan A. et al. Adiponectin: structure, physiological functions, role in diseases, and effects of nutrition. Nutrients. 2021;13(4):1180. DOI: 10.3390/nu13041180Khoramipour K., Chamari K., Hekmatikar A.A., Ziyaiyan A. et al. Adiponectin: structure, physiological functions, role in diseases, and effects of nutrition. Nutrients. 2021;13(4):1180. DOI: 10.3390/nu13041180Francisco V., Pino J., Gonzalez-Gay M.A., Mera A. et al. Adipokines and inflammation: is it a question of weight? British J. Pharmacol. 2018;175(10):1569–79. DOI: 10.1111/bph.14181Francisco V., Pino J., Gonzalez-Gay M.A., Mera A. et al. Adipokines and inflammation: is it a question of weight? British J. Pharmacol. 2018;175(10):1569–79. DOI: 10.1111/bph.14181Вербовой А.Ф., Вербовая Н.И., Долгих Ю.А. Ожирение — основа метаболического синдрома. Ожирение и метаболизм. 2021;18(2):142– 9. DOI: 10.14341/omet12707Verbovoy A.F., Verbovaya N.I., Dolgikh Yu.A. Obesity is the basis of metabolic syndrome. Obesity and Metabolism. 2021;18(2):142–9. (in Russian). DOI: 10.14341/omet12707Han W., Yang S., Xiao H., Wang M. et al. Role of adiponectin in cardiovascular diseases related to glucose and lipid metabolism disorders. Int. J. Mol. Sci., 2022;23(24):15627. DOI: 10.3390/ijms232415627Han W., Yang S., Xiao H., Wang M. et al. Role of adiponectin in cardiovascular diseases related to glucose and lipid metabolism disorders. Int. J. Mol. Sci., 2022;23(24):15627. DOI: 10.3390/ijms232415627Танянский Д.А., Денисенко А.Д. Влияние адипонектина на обмен углеводов, липидов и липопротеинов: анализ сигнальных механизмов. Ожирение и метаболизм. 2021;18(2):103–11. DOI: 10.14341/omet12754Tanyanskiy D.A., Denisenko A.D. The influence of adiponectin on carbohydrates, lipids, and lipoproteins metabolism: analysis of signaling mechanisms. Obesity and Metabolism. 2021;18(2):103–11. (in Russian). DOI: 10.14341/omet12754Lopez-Yus M., Lopez-Perez R., Garcia-Sobreviela M.P., Del Moral-Bergos R. et al. Adiponectin overexpression in C2C12 myocytes increases lipid oxidation and myofiber transition. J. Physiol. Biochem. 2022;78(2):517– 25. DOI: 10.1007/s13105-021-00836-7Lopez-Yus M., Lopez-Perez R., Garcia-Sobreviela M.P., Del Moral-Bergos R. et al. Adiponectin overexpression in C2C12 myocytes increases lipid oxidation and myofiber transition. J. Physiol. Biochem. 2022;78(2):517– 25. DOI: 10.1007/s13105-021-00836-7Wada T., Yamamoto Y., Takasugi Y., Ishii H. et al. Adiponectin regulates the circadian rhythm of glucose and lipid metabolism. J. Endocrinol. 2022;254(2):121–33. DOI: 10.1530/JOE-22-0006Wada T., Yamamoto Y., Takasugi Y., Ishii H. et al. Adiponectin regulates the circadian rhythm of glucose and lipid metabolism. J. Endocrinol. 2022;254(2):121–33. DOI: 10.1530/JOE-22-0006Косыгина А.В. Адипоцитокины в научной и клинической практике. Ожирение и метаболизм. 2011;8(1):32–9. DOI: 10.14341/2071-8713-5189Kosygina A.V. Adipocytokines in scientific and clinical practice. Obesity and Metabolism. 2011;8(1):32–9. (in Russian). DOI: 10.14341/2071-8713-5189Ahl S., Guenther M., Zhao S., James R. et al. Adiponectin levels differentiate metabolically healthy vs unhealthy among obese and nonobese white individuals. J. Clin. Endocrinol. Metab. 2015;100(11):4172–80. DOI: 10.1210/jc.2015-2765Ahl S., Guenther M., Zhao S., James R. et al. Adiponectin levels differentiate metabolically healthy vs unhealthy among obese and nonobese white individuals. J. Clin. Endocrinol. Metab. 2015;100(11):4172–80. DOI: 10.1210/jc.2015-2765Doumatey A.P., Bentley A.R., Zhou J., Huang H. et al. Paradoxical hyperadiponectinemia is associated with the metabolically healthy obese (MHO) phenotype in African Americans. J. Endocrinol. Metab. 2012;2(2):51–65. DOI: 10.4021/jem95WDoumatey A.P., Bentley A.R., Zhou J., Huang H. et al. Paradoxical hyperadiponectinemia is associated with the metabolically healthy obese (MHO) phenotype in African Americans. J. Endocrinol. Metab. 2012;2(2):51–65. DOI: 10.4021/jem95WAguilar-Salinas C.A., García E.G., Robles L., Riaño D. et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J. Clin. Endocrinol. Metab. 2008;93(10):4075–9. DOI: 10.1210/jc.2007-2724Aguilar-Salinas C.A., García E.G., Robles L., Riaño D. et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J. Clin. Endocrinol. Metab. 2008;93(10):4075–9. DOI: 10.1210/jc.2007-2724Панова Е.И., Пиманкина М.С., Каратаева О.В. Клинические особенности и инсулинорезистентность у мужчин с метаболически нездоровым фенотипом ожирения. Архивъ внутренней медицины. 2020;10(4):288–95. DOI: 10.20514/2226- 6704-2020-10-4-288-295Panova E.I., Pimankina M.S., Karataeva O.V. Clinical features and insulin resistance in men with a metabolically unhealthy obesity phenotype. The Russian Archives of Internal Medicine. 2020;10(4):288–95. (in Russian). DOI: 10.20514/2226-6704-2020-10-4-288-295Бояринова М.А., Орлов А.В., Ротарь О.П., Алиева А.С. и др. Адипокины и метаболически здоровое ожирение у жителей Санкт-Петербурга (в рамках эпидемиологического исследования ЭССЕ-РФ). Кардиология. 2016;56(8):40–5. DOI: 10.18565/cardio.2016.8.40-45Boyarinova M.A., Orlov A.V., Rotar O.P., Alieva A.S. et al. Adipokines level in metabolically healthy obese Saint-Petersburg inhabitants (ESSE-RF). Kardiologiia. 2016;56(8):40–5. (in Russian). DOI: 10.18565/cardio.2016.8.40-45Perakakis N., Farr O.M., Mantzoros C.S. Leptin in leanness and obesity: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2021;77(6):745–60. DOI: 10.1016/j.jacc.2020.11.069Perakakis N., Farr O.M., Mantzoros C.S. Leptin in leanness and obesity: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2021;77(6):745–60. DOI: 10.1016/j.jacc.2020.11.069Villanueva-Carmona T., Cedó L., Madeira A., Ceperuelo-Mallafré V. et al. SUCNR1 signaling in adipocytes controls energy metabolism by modulating circadian clock and leptin expression. Cell Metab. 2023;35(4):601–19.e10. DOI: 10.1016/j.cmet.2023.03.004Villanueva-Carmona T., Cedó L., Madeira A., Ceperuelo-Mallafré V. et al. SUCNR1 signaling in adipocytes controls energy metabolism by modulating circadian clock and leptin expression. Cell Metab. 2023;35(4):601–19.e10. DOI: 10.1016/j.cmet.2023.03.004Zhao S., Kusminski C.M., Elmquist J.K., Scherer P.E. Leptin: less is more. Diabetes. 2020;69(5):823–9. DOI: 10.2337/dbi19-0018Zhao S., Kusminski C.M., Elmquist J.K., Scherer P.E. Leptin: less is more. Diabetes. 2020;69(5):823–9. DOI: 10.2337/dbi19-0018Salem A.M. Variation of leptin during menstrual cycle and its relation to the hypothalamic-pituitary-gonadal (HPG) axis: a systematic review. Int. J. Womens Health. 2021;13:445–58. DOI: 10.2147/IJWH.S309299Salem A.M. Variation of leptin during menstrual cycle and its relation to the hypothalamic-pituitary-gonadal (HPG) axis: a systematic review. Int. J. Womens Health. 2021;13:445–58. DOI: 10.2147/IJWH.S309299Jamar G., Caranti D.A., de Cassia Cesar H., Masquio D.C.L. et al. Leptin as a cardiovascular risk marker in metabolically healthy obese: hyperleptinemia in metabolically healthy obese. Appetite. 2017;108:477–82. DOI: 10.1016/j.appet.2016.11.013Jamar G., Caranti D.A., de Cassia Cesar H., Masquio D.C.L. et al. Leptin as a cardiovascular risk marker in metabolically healthy obese: hyperleptinemia in metabolically healthy obese. Appetite. 2017;108:477–82. DOI: 10.1016/j.appet.2016.11.013Смирнова Е.Н., Шулькина С.Г. Содержание лептина, растворимых рецепторов лептина и индекса свободного лептина у больных с метаболическим синдромом. Ожирение и метаболизм. 2017;14(1):30–4. DOI: 10.14341/omet2017130-34Smirnova E.N., Shulkina S.G. Leptin, soluble leptin receptor, and free leptin index in patients with metabolic syndrome. Obesity and Metabolism. 2017;14(1):30–4. (in Russian). DOI: 10.14341/omet2017130-34Macchi C., Greco M.F., Botta M., Sperandeo P. et al. Leptin, resistin, and proprotein convertase subtilisin/kexin type 9: the role of STAT3. Am. J. Pathol. 2020;190(11):2226–36. DOI: 10.1016/j.ajpath.2020.07.016Macchi C., Greco M.F., Botta M., Sperandeo P. et al. Leptin, resistin, and proprotein convertase subtilisin/kexin type 9: the role of STAT3. Am. J. Pathol. 2020;190(11):2226–36. DOI: 10.1016/j.ajpath.2020.07.016Al-Muzafar H.M., Alshehri F.S., Amin K.A. The role of pioglitazone in antioxidant, anti-inflammatory, and insulin sensitivity in a high fatcarbohydrate diet-induced rat model of insulin resistance. Braz. J. Med. Biol. Res. 2021;54(8):e10782. DOI: 10.1590/1414-431X2020e10782Al-Muzafar H.M., Alshehri F.S., Amin K.A. The role of pioglitazone in antioxidant, anti-inflammatory, and insulin sensitivity in a high fatcarbohydrate diet-induced rat model of insulin resistance. Braz. J. Med. Biol. Res. 2021;54(8):e10782. DOI: 10.1590/1414-431X2020e10782Cobos-Palacios L., Ruiz-Moreno M.I., Vilches-Perez A., Vargas-Candela A. et al. Metabolically healthy obesity: inflammatory biomarkers and adipokines in elderly population. PLoS One. 2022;17(6):e0265362. DOI: 10.1371/journal.pone.0265362Cobos-Palacios L., Ruiz-Moreno M.I., Vilches-Perez A., Vargas-Candela A. et al. Metabolically healthy obesity: inflammatory biomarkers and adipokines in elderly population. PLoS One. 2022;17(6):e0265362. DOI: 10.1371/journal.pone.0265362Indulekha K., Surendar J., Anjana R.M., Geetha L. et al. Metabolic obesity, adipocytokines, and inflammatory markers in Asian Indians — CURES-124. Diabetes Technol. Ther. 2015;17(2):134–41. DOI: 10.1089/dia.2014.0202Indulekha K., Surendar J., Anjana R.M., Geetha L. et al. Metabolic obesity, adipocytokines, and inflammatory markers in Asian Indians — CURES-124. Diabetes Technol. Ther. 2015;17(2):134–41. DOI: 10.1089/dia.2014.0202Papadopoulos D.P., Makris T.K., Krespi P.G., Poulakou M. et al. Adiponectin and resistin plasma levels in healthy individuals with prehypertension. J. Clin. Hypertens. (Greenwich). 2005;7(12):729–33. DOI: 10.1111/j.1524-6175.2005.04888.xPapadopoulos D.P., Makris T.K., Krespi P.G., Poulakou M. et al. Adiponectin and resistin plasma levels in healthy individuals with prehypertension. J. Clin. Hypertens. (Greenwich). 2005;7(12):729–33. DOI: 10.1111/j.1524-6175.2005.04888.xTafere G.G., Wondafrash D.Z., Zewdie K.A., Assefa B.T. et al. Plasma adipsin as a biomarker and its implication in type 2 diabetes mellitus. Diabetes Metab. Syndr. Obes. 2020;13:1855–61. DOI: 10.2147/DMSO.S253967Tafere G.G., Wondafrash D.Z., Zewdie K.A., Assefa B.T. et al. Plasma adipsin as a biomarker and its implication in type 2 diabetes mellitus. Diabetes Metab. Syndr. Obes. 2020;13:1855–61. DOI: 10.2147/DMSO.S253967Gu X., Wang L., Liu S., Shan T. Adipose tissue adipokines and lipokines: Functions and regulatory mechanism in skeletal muscle development and homeostasis. Metabolism. 2023;36139:155379. DOI: 10.1016/j. metabol.2022.155379Gu X., Wang L., Liu S., Shan T. Adipose tissue adipokines and lipokines: Functions and regulatory mechanism in skeletal muscle development and homeostasis. Metabolism. 2023;36139:155379. DOI: 10.1016/j. metabol.2022.155379Guo D., Liu J., Zhang P., Yang X. et al. Adiposity measurements and metabolic syndrome are linked through circulating neuregulin 4 and adipsin levels in obese adults. Front. Physiol. 2021;12:667330. DOI: 10.3389/fphys.2021.667330Guo D., Liu J., Zhang P., Yang X. et al. Adiposity measurements and metabolic syndrome are linked through circulating neuregulin 4 and adipsin levels in obese adults. Front. Physiol. 2021;12:667330. DOI: 10.3389/fphys.2021.667330Milek M., Moulla Y., Kern M., Stroh C. et al. Adipsin serum concentrations and adipose tissue expression in people with obesity and type 2 diabetes. Int. J. Mol. Sci. 2022;23(4):2222. DOI: 10.3390/ijms23042222Milek M., Moulla Y., Kern M., Stroh C. et al. Adipsin serum concentrations and adipose tissue expression in people with obesity and type 2 diabetes. Int. J. Mol. Sci. 2022;23(4):2222. DOI: 10.3390/ijms23042222Gómez-Banoy N., Guseh J.S., Li G., Rubio-Navarro A. et al. Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. Nat. Med. 2019;25(11):1739–47. DOI: 10.1038/s41591-019-0610-4Gómez-Banoy N., Guseh J.S., Li G., Rubio-Navarro A. et al. Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. Nat. Med. 2019;25(11):1739–47. DOI: 10.1038/s41591-019-0610-4Lejawa M., Osadnik K., Czuba Z., Osadnik T. et al. Association of metabolically healthy and unhealthy obesity phenotype with markers related to obesity, diabetes among young, healthy adult men. analysis of MAGNETIC Study. Life (Basel). 2021;11(12):1350. DOI: 10.3390/life11121350Lejawa M., Osadnik K., Czuba Z., Osadnik T. et al. Association of metabolically healthy and unhealthy obesity phenotype with markers related to obesity, diabetes among young, healthy adult men. analysis of MAGNETIC Study. Life (Basel). 2021;11(12):1350. DOI: 10.3390/life11121350Wang J.S., Lee W.J., Lee I.T., Lin S.Y. et al. Association between serum adipsin levels and insulin resistance in subjects with various degrees of glucose intolerance. J. Endocr. Soc. 2018;3(2):403–10. DOI: 10.1210/js.2018-00359Wang J.S., Lee W.J., Lee I.T., Lin S.Y. et al. Association between serum adipsin levels and insulin resistance in subjects with various degrees of glucose intolerance. J. Endocr. Soc. 2018;3(2):403–10. DOI: 10.1210/js.2018-00359Климонтов В.В., Булумбаева Д.М., Бгатова Н.П., Таскаева Ю.С. и др. Концентрации адипокинов в сыворотке крови у пациентов с сахарным диабетом 2 типа: взаимосвязи с распределением, гипертрофией и васкуляризацией подкожной жировой ткани. Сахарный диабет. 2019;22(4):336–47. DOI: 10.14341/DM10129Klimontov V.V., Bulumbaeva D.M., Bgatova N.P., Taskaeva Yu.S. et al. Serum adipokine concentrations in patients with type 2 diabetes: the relationships with distribution, hypertrophy and vascularization of subcutaneous adipose tissue. Diabetes Mellitus. 2019;22(4):336–47. (in Russian). DOI: 10.14341/DM10129Kang S., Narazaki M., Metwally H., Kishimoto T. Historical overview of the interleukin-6 family cytokine. J. Exp. Med. 2020;217(5):e20190347. DOI: 10.1084/jem.20190347Kang S., Narazaki M., Metwally H., Kishimoto T. Historical overview of the interleukin-6 family cytokine. J. Exp. Med. 2020;217(5):e20190347. DOI: 10.1084/jem.20190347Kristóf E., Klusóczki Á., Veress R., Shaw A. et al. Interleukin-6 released from differentiating human beige adipocytes improves browning. Exp. Cell Res. 2019;377(1–2):47–55. DOI: 10.1016/j.yexcr.2019.02.015Kristóf E., Klusóczki Á., Veress R., Shaw A. et al. Interleukin-6 released from differentiating human beige adipocytes improves browning. Exp. Cell Res. 2019;377(1–2):47–55. DOI: 10.1016/j.yexcr.2019.02.015Kogelman L.J., Fu J., Franke L., Greve J.W. et al. Inter-tissue gene co-expression networks between metabolically healthy and unhealthy obese individuals. PLoS One. 2016;11(12):e0167519. DOI: 10.1371/ journal.pone.0167519Kogelman L.J., Fu J., Franke L., Greve J.W. et al. Inter-tissue gene co-expression networks between metabolically healthy and unhealthy obese individuals. PLoS One. 2016;11(12):e0167519. DOI: 10.1371/ journal.pone.0167519Князева Л.И., Окрачкова И.В., Бондырева А.В., Маслова Т.А. Динамика показателей активности иммунного воспаления у больных сахарным диабетом типа 2 под влиянием терапии. Современные проблемы науки и образования. 2012;5:21.Knyazeva L.I., Okrachkova I.V., Bondyreva A.V., Maslova T.A. Changes of parameters of immune inflammation activity in patients with type 2 diabetes mellitus undergoing treatment. Modern Problems of Science and Education. 2012;5:21. (in Russian)Терещенко И.В., Каюшев П.Е. Фактор некроза опухоли α и его роль в патологии. Русский медицинский журнал. Медицинское обозрение. 2022;6(9):523–7. DOI: 10.32364/2587-6821-2022-6-9-523-527Tereshchenko I.V., Kayushev P.E. Tumor necrosis factor α and its role in pathologies. Russian Medical Inquiry. 2022;6(9):523–7. (in Russian). DOI: 10.32364/2587-6821-2022-6-9-523-527Ковалева Ю.В. Гормоны жировой ткани и их роль в формировании гормонального статуса и патогенезе метаболических нарушений у женщин. Артериальная гипертензия. 2015;21(4):356– 70. DOI: 10.18705/1607-419X-2015-21-4-356-370Kovalyova Yu.V. Adipose tissue hormones and their role for female fertility and metabolic disorders. Arterial Hypertension. 2015;21(4):356–70. (in Russian). DOI: 10.18705/1607-419X-2015-21-4-356-370Alzamil H. Elevated serum TNF-α is related to obesity in type 2 diabetes mellitus and is associated with glycemic control and insulin resistance. J. Obes. 2020;2020:5076858. DOI: 10.1155/2020/5076858Alzamil H. Elevated serum TNF-α is related to obesity in type 2 diabetes mellitus and is associated with glycemic control and insulin resistance. J. Obes. 2020;2020:5076858. DOI: 10.1155/2020/5076858Lee T.H., Jeon W.S., Han K.J., Lee S.Y. et al. Comparison of serum adipocytokine levels according to metabolic health and obesity status. Endocrinol. Metab. (Seoul). 2015;30(2):185–94. DOI: 10.3803/EnM.2015.30.2.185Lee T.H., Jeon W.S., Han K.J., Lee S.Y. et al. Comparison of serum adipocytokine levels according to metabolic health and obesity status. Endocrinol. Metab. (Seoul). 2015;30(2):185–94. DOI: 10.3803/EnM.2015.30.2.185Cӑtoi A.F., Pârvu A.E., Andreicuț A.D., Mironiuc A. et al. Metabolically healthy versus unhealthy morbidly obese: chronic inflammation, nitrooxidative stress, and insulin resistance. Nutrients. 2018;10(9):1199. DOI: 10.3390/nu10091199Cӑtoi A.F., Pârvu A.E., Andreicuț A.D., Mironiuc A. et al. Metabolically healthy versus unhealthy morbidly obese: chronic inflammation, nitrooxidative stress, and insulin resistance. Nutrients. 2018;10(9):1199. DOI: 10.3390/nu10091199

The authors declare that there are no conflicts of interest present.